Different black box warning labeling for same-class drugs

Journal of General Internal Medicine

Volumn 26, Issue 6, 2011, Pages 603-610

  Panagiotou, Orestis A ^a   Contopoulos Ioannidis, Despina G ^a,b   Papanikolaou, Panagiotis N ^a   Ntzani, Evangelia E ^a   Ioannidis, John P A ^a,b,c,d,e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS MEDICAL CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adverse events; black box warning; FDA; harms

Indexed keywords

ARTICLE; BLACK BOX WARNING; DATA BASE; DRUG CLASSIFICATION; DRUG LABELING; DRUG SAFETY; DRUG WITHDRAWAL;

DATABASES, FACTUAL; DRUG LABELING; HUMANS; PHARMACEUTICAL PREPARATIONS; SAFETY-BASED DRUG WITHDRAWALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79958269378     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1633-9     Document Type: Article

References (48)

1. J Lazarou BH Pomeranz PN Corey 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1200 1205 9555760 10.1001/jama.279.15.1200 1:STN:280:DyaK1c3hsFSnsQ%3D%3D (Pubitemid 28193431)
2. EC Davies CF Green S Taylor PR Williamson DR Mottram M Pirmohamed 2009 Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes PLoS ONE 4 e4439 19209224 10.1371/journal.pone.0004439
3. K Wester AK Jonsson O Spigset H Druid S Hagg 2008 Incidence of fatal adverse drug reactions: a population based study Br J Clin Pharmacol 65 573 579 18070216 10.1111/j.1365-2125.2007.03064.x (Pubitemid 351365134)
4. BL Hug DJ Witkowski CM Sox, et al. 2010 Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention J Gen Intern Med 25 31 38 19894081 10.1007/s11606-009-1141- 3
5. CM Cheng BJ Guglielmo J Maselli AD Auerbach 2010 Coverage of FDA medication boxed warnings in commonly used drug information resources Arch Intern Med 170 831 833 20458094 10.1001/archinternmed.2010.91
6. NS Marks K Weiss 2010 Boxed warnings and other FDA communication tools Am Fam Physician 81 259 20112882
7. BJ Zarowitz 2008 Black box warnings-implications in practice Geriatr Nurs 29 402 409 19064138 10.1016/j.gerinurse.2008.09.005
8. JR Ricci C Coulen JE Berger MC Moore A McQueen SA Jan 2009 Prescriber compliance with black box warnings in older adult patients Am J Manag Care 15 e103 e108 19895180
9. AK Wagner KA Chan I Dashevsky, et al. 2006 FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 15 369 386 16294363 10.1002/pds.1193 (Pubitemid 44018692)
10. Generali JA. Drugs with Black Box Warnings-Comprehensive List. Form Web. Available at http://blackboxrx.com/. Accessed December 28, 2010.
11. DK Wysowski L Swartz 2005 Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions Arch Intern Med 165 1363 1369 15983284 10.1001/archinte.165. 12.1363 (Pubitemid 40973418)
12. JA Generali 2008 The continuing dilemma of drugs with black box warnings Hosp Pharm 43 7 10.1310/hpj4301-7 (Pubitemid 351212420)
13. KE Lasser PD Allen SJ Woolhandler DU Himmelstein SM Wolfe DH Bor 2002 Timing of new black box warnings and withdrawals for prescription medications JAMA 287 2215 2220 11980521 10.1001/jama.287.17.2215 (Pubitemid 34441937)
14. JH Raber 2010 The formulary process from a risk management perspective Pharmacotherapy 30 42S 47S 20500043 10.1592/phco.30.pt2.42S
15. JE Beach GA Faich FG Bormel FJ Sasinowski 1998 Black box warnings in prescription drug labeling: Results of a survey of 206 drugs Food Drug Law J 53 403 411 10346718 1:STN:280:DyaK1MngtFGgsg%3D%3D (Pubitemid 28465030)
16. BA Boucher 2010 Formulary decisions: then and now Pharmacotherapy 30 35S 41S 20500042 10.1592/phco.30.pt2.35S
17. Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]: U.S. Food and Drug Administration 08 July 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm. Accessed December 28, 2010.
18. KE Lasser DL Seger DT Yu, et al. 2006 Adherence to black box warnings for prescription medications in outpatients Arch Intern Med 166 338 344 16476875 10.1001/archinte.166.3.338 (Pubitemid 43244322)
19. BA Liang 2002 FDA use of the black box warning: time for reevaluation as a safety tool J Clin Anesth 14 561 563 12565112 10.1016/S0952-8180(02)00444-0 (Pubitemid 36143655)
20. AS Habib TJ Gan 2008 Pro: The Food and Drug Administration Black box warning on droperidol is not justified Anesth Analg 106 1414 1417 18420854 10.1213/ane.0b013e31816ba463 (Pubitemid 351571070)
21. ER Dorsey A Rabbani SA Gallagher RM Conti GC Alexander 2010 Impact of FDA black box advisory on antipsychotic medication use Arch Intern Med 170 96 103 20065205 10.1001/archinternmed.2009.456
22. K Halloran PG Barash 2010 Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system Curr Opin Anaesthesiol 23 423 427 20446348 10.1097/ACO.0b013e328338c9f7
23. Top 200 Drugs for 2008 by Sales. Available at http://www.drugs.com/ top200.html. Accessed December 28, 2010.
24. PDR® Electronic Library™ 2009, 63rd ed. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc.
25. Drugs@FDA- FDA Approved Drug Products. US Food and Drug Administration/Center for Drug Evaluation and Research. Available at www.accessdata.fda.gov/Scripts/cder/DrugsatFDA. Accessed December 28, 2010.
26. MedWatch Safety Alerts for Human Medical Products. US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm. Accessed December 28, 2010.
27. Food and Drug Administration. CDER Reports to the Nation. Available at http://www.fda.gov/AboutFDA/CentersOffices/CDER/WhatWeDo/ucm078859.htm. Accessed December 28, 2010.
28. Food and Drug Administration. CDER 2000 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2001. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM079006. pdf. Accessed December 28, 2010.
29. Food and Drug Administration. CDER 2001 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2002. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078997. pdf. Accessed December 28, 2010.
30. Food and Drug Administration. CDER 2002 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2003. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078985. pdf. Accessed December 28, 2010.
31. Food and Drug Administration. CDER 2003 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2004. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078975. pdf. Accessed December 28, 2010.
32. Food and Drug Administration. CDER 2004 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2005. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078941. pdf. Accessed December 28, 2010.
33. Food and Drug Administration. CDER 2005 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2005. Available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078935. pdf. Accessed December 28, 2010.
34. Food and Drug Administration. CDER 2007 Update-Improving Public Health Through Human Drugs. Available at http://www.fda.gov/downloads/AboutFDA/ CentersOffices/CDER/WhatWeDo/UCM121704.pdf. Accessed December 28, 2010.
35. FDA's safety information and adverse event reporting program. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm. Accessed December 28, 2010
36. JL Jacoby J Fulton M Cesta M Heller 2005 After the black box warning: dramatic changes in ED use of droperidol Am J Emerg Med 23 196 15765344 10.1016/j.ajem.2004.09.019 (Pubitemid 40349225)
37. A Cheung D Sacks CS Dewa J Pong A Levitt 2008 Pediatric prescribing practices and the FDA black-box warning on antidepressants J Dev Behav Pediatr 29 213 215 18550990 10.1097/DBP.0b013e31817bd7c9
38. CB Nemeroff A Kalali MB Keller, et al. 2007 Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States Arch Gen Psychiatry 64 466 472 17404123 10.1001/archpsyc.64.4.466 (Pubitemid 46556464)
39. K Redmond 2004 The US and European regulatory systems: a comparison J Ambul Care Manage 27 105 114 15069987 (Pubitemid 38365348)
40. NS Rawson 2000 Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998 CMAJ 162 501 504 10701383 1:STN:280:DC%2BD3c7ms1ejsw%3D%3D (Pubitemid 30111990)
41. R Platt M Wilson KA Chan JS Benner J Marchibroda M McClellan 2009 The new Sentinel Network-improving the evidence of medical-product safety N Engl J Med 361 645 647 19635947 10.1056/NEJMp0905338 1:CAS:528:DC%2BD1MXpvFOjtrg%3D
42. JP Ioannidis CD Mulrow SN Goodman 2006 Adverse events: the more you search, the more you find Ann Intern Med 144 298 300 16490917 (Pubitemid 46768214)
43. JP Ioannidis SJ Evans PC Gotzsche, et al. 2004 Better reporting of harms in randomized trials: an extension of the CONSORT statement Ann Intern Med 141 781 788 15545678 (Pubitemid 39524916)
44. DL Sackett WM Rosenberg JA Gray RB Haynes WS Richardson 1996 Evidence based medicine: what it is and what it isn't BMJ 312 71 72 8555924 1:STN:280:DyaK287ktF2itw%3D%3D
45. JP Ioannidis 2009 Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses CMAJ 181 488 493 19654195
46. AB O'Connor 2009 The need for improved access to FDA reviews JAMA 302 191 193 19584349 10.1001/jama.2009.973
47. LM Schwartz S Woloshin 2009 Lost in transmission-FDA drug information that never reaches clinicians N Engl J Med 361 1717 1720 19846841 10.1056/NEJMp0907708 1:CAS:528:DC%2BD1MXhtlams7bI
48. DM Cook RK Gurugubelli LA Bero 2009 Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings Drug Saf 32 1057 1066 19810777 10.2165/11316670-000000000-00000